| アブストラクト | BACKGROUND: Hypersensitivity reactions (HSR) are reported for the macrolides, lincosamides, and streptogramins (MLS) antibiotic family. Data about cross-reactivity among and between MLS remain scarce or controversial. OBJECTIVES: The aim of this study was to provide an overview of hypersensitivity cross-reactions among MLSs based on data extracted from the French National Pharmacovigilance Database (FPVD). METHODS: Cases of HSR to MLSs reported between January 1985 and December 2019 were extracted from the FPVD using standardized MedDRA queries (SMQ). Cases including an allergological test involving multiple MLSs and giving at least one positive result were included. RESULTS: Of the 8394 cases reviewed, 149 were included. HSR mainly involved pristinamycin (n = 83; 53.2%) and spiramycin (n = 31; 19.9%). HSR to MLS was immediate in 54 cases and delayed in 94 cases. Skin tests represented the majority of the allergological tests performed (n = 728; 84.7%), followed by reintroduction tests (n = 79; 9.2%). Eighty-six cross-reactivities among MLS were identified in 62 cases (41.6%). All the 25 explorations performed for streptogramins showed cross-reactivities, but only 30/253 among macrolides (11.9%). Cross-reactivities between the three MLS were observed in 31/322 (9.6%) of the allergological explorations. CONCLUSION: This study highlights the possibility of cross-reactivity among and between MLSs. Dermatologists and allergologists managing patients with HSR to MLSs should be aware of a risk of cross-reactivity among the macrolides and between the different classes of MLS and to perform MLSs allergological testing before recommending an alternative antibiotic, especially in severe drug hypersensitivity from the MLS family. |
|---|
| 投稿者 | Le Baron, Quentin; Bourneau-Martin, Delphine; Babin, Marina; Gouraud, Aurore; Tauber, Marie; Fresse, Audrey; Lebrun-Vignes, Benedicte; Delaunay, Juliette; Morisset, Martine; Briet, Marie |
|---|
| 組織名 | Department of Pharmacology-Toxicology and Pharmacovigilance, University Hospital;of Angers, Angers, France.;CRPV, CHU Lyon, Lyon, France.;Department of Allergology and Clinical Immunology, Inserm 1111 CIRI, CHU Lyon,;Lyon, France.;French Investigators for Skin Adverse Reactions to Drugs (FISARD) group from the;French Society of Dermatology, Paris, France.;CRPV, CHRU Nancy, Nancy, France.;CRPV Paris Pitie-St Antoine, APHP, Sorbonne Universite, Paris, France.;Department of Dermatology, University Hospital of Angers, Angers, France.;Department of Pneumology, University Hospital of Angers, Angers, France.;Univ Angers, Inserm, CNRS, MITOVASC, Equipe CarMe, SFR ICAT, Angers, France. |
|---|
